Hematological Cancers Therapeutics Market to Reach $66.34 Billion By 2026 | Reports And Data

New York, New York, UNITED STATES


High disease prevalence across the globe coupled with ongoing research and development is expected to stimulate market growth

Market Size – USD 31.32 billion in 2018, Market Growth - CAGR of 9.8%, Market Trends – Product launches and research for advanced hematological cancers therapeutics

NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global hematological cancers therapeutics market accounted for USD 31.32 Billion in 2018 and is expected to reach USD 66.34 billion by 2026, at a CAGR of 9.8 percent. Hematology Cancer Therapeutics market is majorly driven by a high incidence of blood cancer across the globe and favorable funding scenario for the research and development of therapeutics for blood cancer. In terms of region, Asia Pacific is estimated to grow at a CAGR of 10.5 % followed by North America with 9.6% percent. 

Additionally, the increase in pressure has driven the market of pharmaceutical companies into the launch of new drugs, considering the upcoming patent expiries of several drugs by 2026. In line with this, key market players focus on the launch of new hematological cancers therapeutics in the market. Owing to the strong presence of pharmaceutical companies and the high prevalence of blood cancer in the region, North America is expected to dominate the hematological cancers therapeutics market during the forecast period.

Request for a sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/1068

Further key findings from the report suggest

  • The market for pharmacological therapies market is projected to grow significantly and deliver a CAGR of 10.5 percent. Owing to pressure for the development of new drugs in lieu of upcoming patent expiries of several drugs by 2026, the leading market players of Hematology Cancer Therapeutics market are focusing on obtaining successful clinical trials to launch new drugs in the market
  • The market for hospitals is anticipated to dominate the market with the revenue of 47.6 billion by 2026. Growth in blood cancer therapeutics market for this segment is supported by reimbursement from government as well as private bodies across the globe.
  • Asia-Pacific will witness a significant rise at a CAGR of 10.5% from 2018 to 2026 in light of favorable government inclination towards the research and development related to blood cancers. Additionally, government hospital spending and infrastructure development rate across the globe has increased by 7 % during the period 2016-2017, with the majority of the new additions being derived from the Asia Pacific region.
  • Key participants include Roche, Celgene, Johnson & Johnson, Karyopharm Therapeutics, Siemens AG, Mindray Medical, Abbott Laboratories, Bio-Rad Laboratories, AbbVie, HemoCue AB, Sysmex, and Novartis.

Make an inquiry for purchasing this report @
https://www.reportsanddata.com/discount-enquiry-form/1068

For the purpose of this report, Reports and Data has segmented the global hematological cancers therapeutics market on the basis of type, end-user, and region:

  • Type Outlook (Revenue, USD Million, 2016 - 2026)
    • Pharmacological Therapies
    • Stem Cell Transplantation
    • Surgery and Radiation Therapy
    • Anemia Treatment
    • Thrombosis Treatment
    • Neutropenia Treatment
    • Others
  • End User Outlook (Revenue, USD Million, 2016 - 2026)
    • Hospitals
    • Clinical Laboratories
    • Academic and Research Institutes
    • Others
  • Regional Outlook (Revenue, USD Million, 2016 - 2026)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • UK
      • The Netherlands
      • Spain
      • Italy
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Rest of Asia-Pacific
    • Middle East Asia
    • Latin America
      • Brazil

Browse More Reports of Pharma and Healthcare Category At: https://www.reportsanddata.com/report/category/pharma-and-healthcare

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John Watson

Head of Business Development

Reports And Data | Web: www.reportsanddata.com

Direct Line: +1-800-819-3052

E-mail: sales@reportsanddata.com

News: www.reportsanddata.com/market-news